Solasia Pharma K.K. provided consolidated financial guidance for the fiscal year ending December 31, 2023. For the year, the company expects revenue in the range of ¥1,000 million to ¥1,800 million, operating loss in the range of ¥1,150 million to ¥350 million, loss in the range of ¥1,150 million to ¥350 million, basic loss per share in the range of ¥6.85 to ¥2.08.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27 JPY | +3.85% | +8.00% | -40.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.00% | 30.06M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.98% | 31.28B | |
+57.86% | 25.27B | |
-16.24% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
-17.10% | 11.69B | |
+6.89% | 8.83B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023